ARCHIVES

In Brief: David Feigal To Head FDA’s Antiviral Division; ODAC To Discuss Melphalan, Amifostine NDAs

This article is from The Cancer Letter archive.

Vol. 18 No. 03 | January 17, 1992

Download PDF Visit The Full Archive

Related Articles

NCI-Approved Clinical Trials

July 28, 2006

Costs of Rosenberg Regimen Could Hinder cooperative Group Trials

January 3, 1986

Study Identifies Women Likely To Benefit From Therapy With Aromatase Inhibitors

November 24, 2006

Rabson Replaces Berlin At Div. Of Biology, Diagnosis

February 14, 1975

Beckman Coulter Offers Immunoassay System.

July 27, 2001

Troubled Roswell Park Cancer Institute Bets On Recruitment To Regain Its Luster.

January 19, 2001